Clinical Trial Update: A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating BI 685509 alone or with empagliflozin for liver cirrhosis due to viral hepatitis or non-alcoholic steatohepatitis with portal hyperte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Non-alcoholic Steatohepatitis
• Portal Hypertension
• Viral Hepatitis

Drugs mentioned

• BI 685509
• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Liver Diseases, Hypertension, Portal | Phase 2 | Status: TERMINATED | Results posted: 2025-04-29